NEW YORK (GenomeWeb) – Agendia today announced a new deal with Daiichi Sankyo to use Agendia's oncology biomarker technology to evaluate new drugs from the Japanese drug firm currently in clinical trials.
As part of the deal, Agendia's technology will be used to assess patient samples. Financial and other terms were not disclosed.